Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future
about
Recent advances in multidisciplinary management of hepatocellular carcinomaHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsSurveillance, diagnosis, treatment, and outcome of liver cancer in JapanAssessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patientsProliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithineProliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine.Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway.Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma.0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loopCo-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinomaDifferentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.Diosmetin inhibits cell proliferation and induces apoptosis by regulating autophagy via the mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells.NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.Cell death in a co-culture of hepatocellular carcinoma cells and human umbilical vascular endothelial cells in a medium lacking glucose and arginineReview of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.Current management of hepatocellular carcinoma: an Eastern perspective.Surgical and Locoregional Therapy of HCC: TACE.Establishment of experimental implantation tumor models of hepatocellular carcinoma in Wistar rats.Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.Tissue factor pathway inhibitor-2 induced hepatocellular carcinoma cell differentiation.Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal AblationMolecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma.Decorin-loaded poly lactic-co-glycolic acid nanoparticles modified by anti-alpha fetoprotein antibody: preparation, proliferation inhibition and induced apoptosis effects on HepG2 cells in vitro.Identification of Small Molecule Modulators of MicroRNA by Library Screening.
P2860
Q26863748-5AFD21FF-BF9A-453E-9FFA-0E5D667AE7C9Q28078111-8A870893-8F4F-4E03-8CD7-9E97FA0AB061Q28082702-91CAD870-DC65-4010-A2FC-8B852E90EF15Q28086977-1287977B-2843-4DCE-9B0B-3914E7E5B2A1Q33598120-83537A70-EE64-49FE-8944-F5ABC852740CQ33599232-EBC738D2-550F-411C-8D1C-6E9766565A92Q33823252-A494136E-007C-48EE-8C94-591D95C6C05CQ33837248-8BEBB78B-350E-417A-9184-D8581A57B8C5Q33861041-286637BC-543E-4D1E-9A8B-B9F76F526E70Q34265415-7F2F57FF-C0EE-4B3B-93D8-A7CE3948EC91Q35128190-3E691F94-4204-4D33-88BB-D29BF6EEBBFFQ36609684-7B047BED-5F1D-4175-A311-4A9A166E7DF1Q37581764-4E42B82B-89CD-4184-8E14-27E0D80F77B8Q37588101-17405DC6-5B95-4A36-81CF-4EB7EA622517Q37594086-2AF43B70-4C04-430D-A7A2-06928DF22168Q38334020-4F26A7EB-A800-46B8-ACF1-7EAC944B231EQ38410816-72D1CCE9-DBDB-41B7-A2AE-8B30792F7E56Q38671236-507D1802-2930-4DD7-BF38-A429B6F29220Q38986377-2DE2BF32-E42E-4CD6-8ECE-E2ADB1304B9AQ39270408-2DE9BB73-C9DF-48EA-96C2-ABB3E69177C8Q40277662-D1F21A9C-7849-40C3-9749-D136545D919BQ41479551-D972E60D-C555-4F1C-98F6-F3EED9D4B78BQ42169289-C339E63B-1A32-434F-98EF-3A8B23DC7429Q44408295-419FBBFB-65B2-468B-9A1D-68B43F7DA8C0Q50859040-9CC409EB-9883-4CF1-A98B-204CFAF5721FQ51282058-BAF2F4F8-1FB4-451E-B715-FA5598135FDF
P2860
Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical trials of combined mo ...... oma: past, present, and future
@ast
Clinical trials of combined mo ...... oma: past, present, and future
@en
Clinical trials of combined mo ...... oma: past, present, and future
@nl
type
label
Clinical trials of combined mo ...... oma: past, present, and future
@ast
Clinical trials of combined mo ...... oma: past, present, and future
@en
Clinical trials of combined mo ...... oma: past, present, and future
@nl
prefLabel
Clinical trials of combined mo ...... oma: past, present, and future
@ast
Clinical trials of combined mo ...... oma: past, present, and future
@en
Clinical trials of combined mo ...... oma: past, present, and future
@nl
P2860
P3181
P356
P1433
P1476
Clinical trials of combined mo ...... oma: past, present, and future
@en
P2093
Hwi Young Kim
Joong-Won Park
P2860
P3181
P356
10.1159/000343854
P407
P577
2014-03-01T00:00:00Z